Weight and metabolic changes among virally-suppressed people with HIV who switched to co-formulated bictegravir/emtricitabine/tenofovir alafenamide
Journal
Journal of global antimicrobial resistance
Date Issued
2024-03
Author(s)
Hsu, Jen-Yu
Chen, Ling-Ya
Su, Yi-Ching
Liu, Wen-Chun
Abstract
We aimed to investigate the evolution of weight, lipid profiles, and glucose homeostasis among virally-suppressed people living with HIV (PLWH) who switched to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF).
Subjects
antiretroviral therapy; diabetes mellitus; dyslipidemia; integrase strand-transfer inhibitors; nucleotide reverse-transcriptase inhibitor; weight gain
SDGs
Type
journal article